Synthesis, Biological Activity and Molecular Modeling of 4-Fluoro-N-[ω-(1,2,3,4-tetrahydroacridin-9-ylamino)-alkyl]-benzamide Derivatives as Cholinesterase Inhibitors

P. Szymański; M. Markowicz; M. Bajda; B. Malawska; E. Mikiciuk-Olasik

doi:10.1055/s-0032-1329963

Arzneimittelforschung, Inhaltsverzeichnis

Arzneimittelforschung 2012; 62(12): 655-660
DOI: 10.1055/s-0032-1329963

Original Article

Synthesis, Biological Activity and Molecular Modeling of 4-Fluoro-N-[ω-(1,2,3,4-tetrahydroacridin-9-ylamino)-alkyl]-benzamide Derivatives as Cholinesterase Inhibitors

Authors

P. Szymański

¹Department of Pharmaceutical Chemistry and Drug Analyses, Medical University, Lodz, Poland
M. Markowicz

¹Department of Pharmaceutical Chemistry and Drug Analyses, Medical University, Lodz, Poland
M. Bajda

²Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland
B. Malawska

²Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland
E. Mikiciuk-Olasik

¹Department of Pharmaceutical Chemistry and Drug Analyses, Medical University, Lodz, Poland

Abstract

The aim of this study was to synthesize and determine the biological activity of new derivatives of 4-fluorobenzoic acid and tetrahydroacridine towards inhibition of cholinesterases. Compounds were synthesized in condensation reaction between 9-aminoalkyl-tetrahydroacridines and the activated 4-fluorobenzoic acid. Properties towards inhibition of acetyl- and butyrylcholinesterase were estimated according to Ellman’s spectrophotometric method. Among synthesized compounds the most active were compounds 4a and 4d. These compounds, in comparison with tacrine, were characterized by the similar values of IC₅₀. Among all obtained compounds, 4d presented the highest selectivity towards inhibition of acetylcholinesterase. Molecular modeling studies revealed that all derivatives presented similar extended conformation in the gorge of acetylcholinesterase, however, there were 2 main conformations in the active center of butyrylcholinesterase: bent and extended conformation.

Key words

Alzheimer’s disease - tacrine - fluorobenzoic acid - docking - Ellman’s method

Volltext

Referenzen

References
1 Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet 2006; 368: 387-403
2 Weiner MW, Aisen PS, Jack CR et al. The Alzheimer’s disease neuroimaging initiative: progress report and future plans. Alzheimer Dement 2010; 6: 202-211
3 Mucke L. Neuroscience: Alzheimer’s disease. Nature 2009; 461: 895-897
4 Petrella JR, Coleman E, Doraiswamy PM. Neuroimaging and Early Diagnosis of Alzheimer Disease. Radiology 2003; 226: 315-336
5 Greig NH, Utsuki T, Ingram DK et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer -amyloid peptide in rodent. P Natl Acad Sci 2005; 102 (47) 17213-17218
6 Ryu EK, Choe YS, Park EY et al. Synthesis and evaluation of 2-[¹⁸F]fluoro-CP-118,954 for the in vivo mapping of acetylcholinesterase. Nucl Med Biol 2005; 32: 185-191
7 Tavitian B, Pappata S, Bonnot-Lours S et al. Positron emission tomography study of [11C]methyl-tetrahydroaminoacridine (methyl-tacrine) in baboon brain. Eur J Pharmacol 1993; 236: 229-238
8 Pappata S, Tavitian B, Traykov L et al. In Vivo Imaging of Human Cerebral Acetylcholinesterase. J Neurochem 1996; 67: 876-879
9 Lee S-Y, Choe YS, Sugimoto H et al. Synthesis and biological evaluation of 1-(4-[18F]fluorobenzyl)-4- [(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine for in vivo studies of acetylcholinesterase. Nucl Med Biol 2000; 27: 741-744
10 Choe YS, Oh SJ, Shim I et al. Syntheses and biological evaluation of 18F-labeled 3-(1-benzylpiperidin-4-yl)-1-(1-methyl-1H-indol-3-yl)propan-1-ones for in vivo mappingof acetylcholinesterase. Nucl Med Biol 2000; 27: 263-267
11 Liston DR, Nielsen JA, Villalobos A et al. Pharmacology of selective acetylcholinesterase inhibitors: Implications for use in Alzheimer’s disease. Eur J Pharmacol 2004; 486: 9-17
12 Pakaski M, Kalman J. Interactions between the amyloid and cholinergic mechanisms in Alzheimer’s disease. Neurochem Int 2008; 53: 103-111
13 Sabbagh NM, Richardson S, Relkin N. Disease-modifying approaches to Alzheimer’s disease: Challenges and opportunities-lessons from donepezil therapy. Alzheimer Dement 2008; 4: 109-118
14 Hagmann WK. The Effect of Fluorine Substitution on. pKa. J Med Chem 2008; 51: 4359-4369
15 Hu M-K, Wu L-J, Hsiao G et al. Homodimeric Tacrine Congeners as Acetylcholinesterase Inhibitors. J Med Chem 2002; 11: 2277-2282
16 Szymański P, Karpiński A, Mikiciuk-Olasik E. Synthesis, biological activity and HPLC validation of 1,2,3,4-tetrahydroacridine derivatives as acetylcholinesterase inhibitors. Eur J Med Chem 2011; 46: 3250-3257
17 Carlier PR, Du DM, Han Y et al. Potent, Easily Synthesized Huperzine A-Tacrine Hybrid Acetylcholinesterase Inhibitors. Bioorg Med Chem Lett Aug 1999; 9 (16) 2335-2338
18 Szymanski P, Markowicz M, Mikiciuk-Olasik E. Synthesis and biological activity of derivatives of tetrahydroacridine as acetylcholinesterase inhibitors. Bioorg Chem 2011; 39 (04) 138-142
19 Dorronsoro I, Alonso D, Castro A et al. Synthesis and Biological Evaluation of Tacrine-Thiadiazolidinone Hybrids as Dual Acetylcholinesterase Inhibitors. Arch Pharm Chem Life Sci 2005; 338: 18-23
20 Carlier PR, Han YF, Chow ES-W et al. Evaluation of short-tether Bis-THA AChE inhibitors. A further test of the dual binding site hypothesis. Bioorg Med Chem 1999; 7: 351-357
21 Rosini M, Andrisano V, Bartolini M et al. Rational Approach to discover multipotent anti-Alzheimer drugs. J Med Chem 2005; 48: 360-363
22 Fang L, Kraus B, Lehmann J et al. Tacrine–ferulic Acid Hybrids as Multi-potent Anti-Alzheimer Drug Candidates. Bioorg Med Chem 2008; 18: 2905-2909
23 Carlier PR, Chow ES-W, Han YF et al. Heterodimeric Tacrine-Based Acetylcholinesterase Inhibitors: Investigating Ligand − Peripheral Site Interactions. J Med Chem 1999; 42: 4225-4231
24 Fang L, Appenroth D, Decker M et al. Tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity. J Med Chem 2008; 51: 7666-7669
25 Kamiński ZJ. 2-Chloro-4,6-dimethoxy-1,3,5-triazine. A New Coupling Reagent for Peptide Synthesis. Synthesis 1987; 917-920
26 Blotny G. Recent applications of 2,4,6-trichloro-1,3,5-triazine and its derivatives in organic synthesis. Tetrahedron 2006; 62: 9507-9522
27 Ellman GL, Courtney KD, Andres V et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharm 1961; 7: 88-95
28 Cheng YC, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharm 1973; 22: 3099-3108
29 Tipton KF. Commentary: Enzyme kinetics in relation to enzyme inhibitors. Biochem Pharm 1973; 22: 2933-2941
30 Szymański P, Markowicz M, Bajda M et al. Synthesis and biological activity of new 2,3-dihydro-1H-cyclopenta[b]quinoline derivatives as acetylcholinesterase inhibitors. Lett Drug Des Discov 2012; 9: 645-654

Zusatzmaterial

Supporting information (PDF)